Loading clinical trials...
Loading clinical trials...
A Multicenter, Dose-optimized, Double-blind, Randomized, Placebo-controlled Study To Evaluate The Efficacy Of Nwp09 In Pediatric Patients With Attention Deficit Hyperactivity Disorder (Adhd) In A Laboratory Classroom
The safety and efficacy of a chewable formulation of extended-release methylphenidate will be studied in children with ADHD
Age
6 - 12 years
Sex
ALL
Healthy Volunteers
No
Clinical Study Centers, LLC
Little Rock, Arkansas, United States
Laboratory School
Huntington Beach, California, United States
UC Irvine Child Development Center
Irvine, California, United States
UC Irvine - Hewitt Hall
Irvine, California, United States
Florida Clinical Research Center, LLC
Bradenton, Florida, United States
Woodland Community Church (Laboratory School)
Bradenton, Florida, United States
Center for Psychiatry and Behavioral Medicine, Inc.
Las Vegas, Nevada, United States
Bayou City Research, Ltd.
Houston, Texas, United States
Westex Clinical Investigations
Lubbock, Texas, United States
Start Date
July 1, 2012
Primary Completion Date
October 1, 2012
Completion Date
October 1, 2012
Last Updated
February 3, 2016
90
ACTUAL participants
NWP09
DRUG
Placebo
DRUG
Lead Sponsor
Pfizer
NCT07189442
NCT06123741
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06847165